Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis (RADIANT-TB)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03851588|
Recruitment Status : Recruiting
First Posted : February 22, 2019
Last Update Posted : January 18, 2020
|Condition or disease||Intervention/treatment||Phase|
|HIV Infections Tuberculosis||Other: Placebo Drug: Dolutegravir 50 mg||Phase 2|
Dolutegravir is being rolled out to replace efavirenz in first-line antiretroviral therapy (ART) in low-middle income countries (LMICs) because it is more effective, better tolerated, and has a considerably higher genetic barrier to resistance.
Tuberculosis is the commonest cause of HIV-related morbidity and mortality in LMICs. Rifampicin, which is a key component of anti-tuberculosis therapy, induces genes that are important in the metabolism and transport of dolutegravir. The resulting drug-drug interaction between dolutegravir and rifampicin significantly reduces dolutegravir exposure, which can be overcome by increasing the dose of dolutegravir to 50 mg 12 hourly.
The additional dose of dolutegravir will be difficult to implement in high burden settings. Furthermore, the additional dolutegravir tablet increases pill burden and costs. If standard dose dolutegravir is shown to be effective in patients with tuberculosis this would sweep away one of the major barriers to its implementation in LMICs. There are three lines of evidence to support studying standard dose dolutegravir in patients with HIV-associated tuberculosis.
First, there are compelling pharmacokinetic and pharmacodynamic data supporting the therapeutic efficacy of lower dolutegravir exposure. Second, the investigators have conducted a drug-drug interaction study of dolutegravir dosed at 50 mg or 100 mg once daily in healthy volunteers with rifampicin. Although, as expected, concomitant rifampicin significantly reduced dolutegravir exposure at both doses, all dolutegravir trough concentrations on rifampicin were above the protein-adjusted 90% inhibitory concentration (PA IC90). Third, exposure to the first-generation integrase inhibitor raltegravir is also significantly reduced with concomitant rifampicin. A phase 2 study in patients with HIV-associated tuberculosis showed that virologic outcomes were similar with standard and double dose raltegravir. It is plausible that findings could be similar with dolutegravir.
The hypothesis is that virologic outcomes with standard dose dolutegravir-based ART will be acceptable in patients on rifampicin-based anti-tuberculosis therapy. If the proportion of participants who achieve virological suppression on standard dose dolutegravir is acceptable, this would pave the way for a phase 3 trial of dolutegravir 50 mg daily versus an appropriate standard of care regimen, like efavirenz-based ART, in patients with HIV-associated tuberculosis.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||108 participants|
|Intervention Model:||Parallel Assignment|
|Intervention Model Description:||Parallel assignment of randomised groups|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||Standard Versus Double Dose Dolutegravir in Patients With HIV-associated Tuberculosis: a Phase 2 Non-comparative Randomised Controlled Trial|
|Actual Study Start Date :||December 19, 2019|
|Estimated Primary Completion Date :||June 30, 2021|
|Estimated Study Completion Date :||December 31, 2021|
Active Comparator: Supplementary dose
Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with an additional dolutegravir 50 mg dose taken 12 hours later.
Drug: Dolutegravir 50 mg
Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is given with a supplementary dose of dolutegravir 50 mg.
Other Name: Tivicay 50 mg
Placebo Comparator: Placebo dose
Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily with placebo taken 12 hours later.
Dolutegravir-lamivudine-tenofovir fixed-dose combination tablet daily is not given with a supplementary dose of dolutegravir 50 mg.
- Virological suppression at 24 weeks [ Time Frame: 24 weeks ]Proportion with HIV viral load <50 copies/mL at 24 weeks analysed by modified intention to treat (ITT), which includes all participants who received at least one dose of dolutegravir, and according to the FDA snapshot algorithm.
- Virological suppression at 12 weeks (modified ITT) [ Time Frame: 12 weeks ]Proportion with HIV viral load <50 copies/mL at 12 weeks analyzed modified ITT.
- Virological suppression at 12 and 24 weeks (per protocol) [ Time Frame: 12 and 24 weeks ]Proportion with HIV viral load <50 copies/mL at 12 and 24 weeks analyzed per protocol.
- Virological suppression at 48 weeks (modified ITT) [ Time Frame: 48 weeks ]Proportion with HIV viral load <50 copies/mL at 48 weeks analyzed modified ITT.
- Virological suppression at 48 weeks (per protocol) [ Time Frame: 48 weeks ]Proportion with HIV viral load <50 copies/mL at 48 weeks analyzed per protocol.
- CD4 change at 24 and 48 weeks [ Time Frame: 24 and 48 weeks ]Change in CD4 count from screening at week 24 and week 48.
- Dolutegravir trough concentrations [ Time Frame: 4, 8, 12, 24, and 48 weeks ]Proportion with dolutegravir trough concentrations above the PA IC90 at weeks 4, 8, 12, 24, and 48.
- Grade 3 or 4 adverse events [ Time Frame: 48 weeks ]Grade 3 or 4 drug-related adverse events will be accessed throughout the trial.
- Change in sleep assessment from baseline [ Time Frame: 4, 8, 12, 16, 20, 24, and 48 weeks ]
Insomnia severity scale - measures sleep patterns and how this influences daily functioning and quality of life (assessed at weeks 4, 8, 12, 16, 20, 24, and 48).
Please rate the current (i.e. last 2 weeks) severity of your insomnia problem(s):
None, Mild, Moderate, Severe, Very Severe
- How satisfied/dissatisfied are you with your current sleep pattern? 0 - 5 (Very Satisfied - Very Dissatisfied)
- To what extent do you consider your sleep problem to interfere with your daily functioning? 0 - 4 (Not interfering at all, A little, Somewhat, Much, Interfering very much)
- How noticeable to others do you think your sleeping problem is in terms of impairing the quality of your life? 0 - 4 (Not noticeable at all, Barely, Somewhat, Much, Very much noticeable)
- How worried/distressed are you about your current sleep problem? 0 - 4 (Not noticeable at all, A little, Somewhat, Much, Very much)
- Change in mental health assessment from baseline [ Time Frame: 12, 24, and 48 weeks ]Mental health will be assessed by a questionnaire given at baseline, 12 weeks, 24 weeks, and 48 weeks. The questionnaire is standardized and has been based on the mini international neuropsychiatric interview (version 7.0.0). All questions in the questionnaire require a yes/no answer.
- Serious adverse events [ Time Frame: 48 weeks ]Document any serious adverse events that occur throughout the trial.
- Adverse events requiring discontinuation of an ART drug [ Time Frame: 48 weeks ]Any adverse event that requires discontinuation of any drug in the ART regimen throughout the trial.
- Antiretroviral resistance mutations testing by genotypic resistance assay in participants with virologic failure [ Time Frame: 24 and 48 weeks ]If a viral load is >1000 copies/mL at week 24 or at week 48, or if the viral load was suppressed and then rebounded to >1000 copies/mL, a sample will be taken for resistance testing. Antiretroviral resistance mutations in participants with virologic failure will be assessed by genotypic resistance assay and compared to stored plasma at baseline to distinguish emergent from pre-treatment resistance.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03851588
|Contact: Gary Maartens, MMedfirstname.lastname@example.org|
|Contact: Graeme Meintjes, PhDemail@example.com|
|Khayelitsha Site B/Ubuntu Clinic||Recruiting|
|Cape Town, Western Cape, South Africa, 8001|
|Contact: Rulan Griesel, MMed +27216501992 firstname.lastname@example.org|
|Principal Investigator: Gary Maartens, MMed|
|Sub-Investigator: Rulan Griesel, MMed|
|Principal Investigator:||Gary Maartens, MMed||University of Cape Town|